Showing results (261-270 of 275) with videos related to

Sort By:
Pageof 28
ACS Medicinal Chemistry Letters|August 22, 2018
Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug ConjugatesAlexei S Karpov, Tinya Abrams, Suzanna Clark, et al.
Diabetes|November 5, 2013
GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in ratsKirk M Habegger, Kristy M Heppner, Sarah E Amburgy, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|July 3, 2010
Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbiditiesRohit Kohli, Michelle Kirby, Kenneth D R Setchell, et al.
Diabetes|June 19, 2013
GLP-1R agonism enhances adjustable gastric banding in diet-induced obese ratsKirk M Habegger, Henriette Kirchner, Chun-Xia Yi, et al.
Mabs|January 6, 2025
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificityAlyssa Synan, Nila C Wu, Roberto Velazquez, et al.
Blood Cancer Journal|May 30, 2015
A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignanciesS Y Kim, J-W Theunissen, J Balibalos, et al.
JCI Insight|July 31, 2020
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistFrancis S Willard, Jonathan D Douros, Maria Bn Gabe, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Legacy Effects of Early β-Adrenergic Stimulation Program Adipose Plasticity and Confer Metabolic Resilience in ObesityPablo E Morales, Wenxin Tong, Lavanya Vishvanath, et al.
Molecular Metabolism|February 7, 2026
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analoguesJonathan D Douros, Megan Capozzi, Aaron Novikoff, et al.
The Journal of Clinical Investigation|June 17, 2025
β Cell Gαs signaling is critical for physiological and pharmacological enhancement of insulin secretionMegan E Capozzi, David Bouslov, Ashot Sargsyan, et al.
Pageof 28